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ABSTRACT: Advances in biotechnology necessitate both an understanding of scientific
principles and ethical implications to be clinically applicable in medicine. In this regard,
therapeutic cloning offers significant potential in regenerative medicine by circumventing
immunorejection, and in the cure of genetic disorders when used in conjunction with gene
therapy. Therapeutic cloning in the context of cell replacement therapy holds a huge potential
for de novo organogenesis and the permanent treatment of Parkinson's disease, Duchenne
muscular dystrophy, and diabetes mellitus as shown by in vivo studies. Scientific roadblocks
impeding advancement in therapeutic cloning are tumorigenicity, epigenetic reprogramming,
mitochondrial heteroplasmy, interspecies pathogen transfer, low oocyte availability.
Therapeutic cloning is also often tied to ethical considerations concerning the source,
destruction and moral status of IVF embryos based on the argument of potential. Legislative
and funding issues are also addressed. Future considerations would include a distinction
between therapeutic and reproductive cloning in legislative formulations. 
KEYWORDS: therapeutic cloning, SCNT, cell replacement therapy, gene therapy,
mitochondrial heteroplasmy, oocyte availability, biomedical ethics
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INTRODUCTION
The advancement in biotechnologies and stem cell
research, although encountering many scientific
difficulties, legal constraints and ethical roadblocks,
offers a tremendous potential in regenerative medicine
and in the treatment of genetic defects. Therapeutic
cloning is the transfer of nuclear material isolated from
a somatic cell into an enucleated oocyte in the goal of
deriving embryonic cell lines with the same genome as
the nuclear donor. Somatic cell nuclear transfer (SCNT)
products have histological compatibility with the
nuclear donor, which circumvents, in clinical
applications, the use of immunosuppressive drugs with
heavy side-effects. While the goal of reproductive
cloning is the creation of a person, the purpose of
therapeutic cloning is to generate and direct the
differentiation of patient-specific cell lines isolated
from an embryo not intended for transfer in utero.
Therapeutic cloning, through the production of these
autologous nuclear-transfer embryonic stem cells
(ntESC), offers great promises for regenerative and
reproductive medicine, and in gene therapy, as a vector
for gene-delivery. This review focuses on the recent
breakthroughs in research based on therapeutic cloning,
their feasibility, and their potential applications in
medicine. The second part of this review discusses
current roadblocks of therapeutic cloning, both in
science and biomedical ethics, as well as the main
alternatives to therapeutic cloning. 
Procedure for SCNT and characteristics of the
ntESC
The procedure  for SCNT does not differ from that of
reproductive cloning (1). The host oocyte is arrested at
metaphase II (2), and immobilized through light suction
exerted by a pipette tip. A glass needle is used to remove
a small piece of the zona pellucida and is reinserted
through this puncture to extract the polar body and the
oocyte nuclei. The incorporation of the somatic nuclei
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into the enucleated oocyte can be done through
electrofusion, which is the application of an electric
pulse to incorporate a mammalian cell into the oocyte
(used to produce Dolly). Alternatively, a somatic
nucleus can be injected in the perivitelline space, the
fluid-filled region between the zona pellucida and the
ooplasm, as was used for Cumulina, the first mouse
cloned through SCNT. Mitosis occurs in vitro until the
formation of the blastocyst, a fluid-filled hollow ball of
cells (40-150 cells) to which is attached, from the
inside, the embryoblast or inner cell mass from which
ntESC are taken. Subsequent addition of cell-type
specific markers and growth hormones promotes the
differentiation of the ntESC into the desired cell-line to
be implanted in vivo inside the nuclear donor for
therapeutic purposes, in cell replacement therapy for
instance. In vitro, the ESC can proliferate ad infinitum
and are totipotent, capable of differentiating into any
cell-type of the body, contrary to adult stem cells which
are multipotent, namely committed to produce any type
of cells pertaining to a particular lineage (3).
Current legal status of therapeutic cloning in
relation to reproductive cloning 
Laws regarding biomedicine are generally formulated
in vague terms that do not distinguish reproductive from
therapeutic cloning. The Convention on Human Rights
and Biomedicine (Oviedo convention), formulated by
the Council of Europe in 1997, is counterintuitive.
Article 13 declares that "an intervention seeking to
modify the human genome may be only undertaken for
preventive, diagnostic or therapeutic purposes" and
stipulates in Article 18 that "the creation of human
embryos for research is prohibited (4)." The Protocol on
Cloning, put forward in 1998 and signed by 19
European nations, bans reproductive cloning and was
paradoxically signed by France and Germany, which
both have permissive policies regarding the generation
of human ntESC lines. 
Committees are formed in different countries to
debate and regulate cloning, such as the President's
Council on Bioethics, created in the USA in 2002,
which is a much less permissive group than the UK's
Human Fertilization and Embryology Authority
(HFEA). The legitimacy of the latter is being
questioned by the Prolife movement under the pretext
that they were not democratically elected (5). Canada's
Assisted Human Reproduction Act, in vigor since 2004,
allows stem cell research only on unimplanted embryos
obtained from fertility clinics but forbids SCNT (6).
Asia has the highest legal permissibility since the
generation of human ntESC lines through SCNT is legal
(25). Australia is currently reviewing its existing laws
(7)  to follow the Asian trend in Singapore, China and
South Korea, and to legalize the generation of chimeras
using human DNA. 
Since both reproductive and therapeutic cloning
require the in vitro generation of a human embryo,
prohibiting reproductive cloning is likely to result in
severely hindering medically important research based
on therapeutic cloning. A worldwide ban on
reproductive human cloning was proposed by France
and Germany to the UN in 2001 and effective4 since
September 2006 (4). A breakthrough in reproductive
cloning was published a month earlier by Zavos and
Illmensee, who injected a skin fibroblast nucleus from
an infertile man into an oocyte provided by his wife.
One out of three SCNT attempts was successful, and
although the four-celled embryo failed to implant in
utero, this is the "first evidence of the creation and
transfer of a human cloned embryo for reproductive
purposes (8)." One may infer, from the rigidity of the
current legislature regarding therapeutic cloning and
stem cell research, that legal constraints are motivated
by the fear that scientific development will be faster
than the legislative debate, which was almost the case
with Zavros and Illmensee's breakthrough, and lead to
the unregulated reproductive cloning of human beings.  
Promises of therapeutic cloning
SCNT in the context of therapeutic cloning holds a
huge potential for research and clinical applications
including the use of SCNT product as a vector for gene
delivery, the creation of animal models of human
diseases, and cell replacement therapy in regenerative
medicine. Furthermore, SCNT might, in the future,
allow in vitro organogenesis and counteract senescence.
The combination of therapeutic cloning and gene
therapy offers a great potential for patient-specific
rescue of a genetic mutation of the loss-of-function
type, resulting in lowered or eliminated activity of a
particular protein. Therapeutic cloning used in cell
replacement therapy has the potential to create various
types of tissues such as osteoblasts to counteract
osteoporosis, and spinal cord regeneration following
trauma, as shown by Deshpande et al, who transferred
motor neurons derived from ESC to rats with a severed
spinal cord (9). The resulting recovery of motility could
lead to clinical applications for paralysis in humans
through therapeutic cloning. 
Applications in regenerative medicine: recent
breakthroughs for diabetes and neurodegenerative
diseases
Therapeutic cloning constitutes a promising tool in
tissue engineering and might offer the possibility of
synthesizing organs de novo, which would solve the
problems of immune rejection and organ shortage for
transplantation. The assembly of patient-specific
cardiomyocytes, blood vessels and skin pieces fixed on
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type embryo of the same developmental stage (39). The
rejuvenating potential conferred by SCNT can be
paradoxically thwarted by telomere shortening, which
reflects both the biological age of the nuclear donor and
the time during which the ntESC lines were grown (37),
leading to premature aging also observed in cloned
animals. However, the addition of a transgene
containing the two coding regions needed for the
production of telomerase could restore telomere lengths
and thus increase the survival of the transplanted cells,
which would increase the success rate of therapeutic
cloning for regenerative medicine. This strategy needs
more investigation to be feasible because, while
telomere length would not trigger tumorigenesis (12),
Stampfer et al showed that, knockout p16INK4a
epithelial cells with no endogenous telomerase activity
do not respond to the pro-apoptotic signals of the
growth factor TGF-ß following the addition of high
levels of hTERT, the telomerase catalytic subunit (13). 
GENERATING ANIMAL MODELS ANIMAL
MODELS OF HUMAN DISEASE 
Animal models of human diseases can be designed
through therapeutic cloning for research purposes.
Although a viable nonhuman primate has not yet been
produced by SCNT, the success of Mitalipov and Wolf
in creating a monkey by embryonic cloning from the
nucleus of an allogenic blastomere supported the
possibility that, through gene targeting, genetic defects
can be reproduced in a wild-type genome to express a
loss of function (14). Hence, we are getting one step
closer to patient-specific genetic engineering of animal
models of human disease. With improved SCNT
protocol, the nucleus of a patient's skin biopsy could be
introduced into a primate or mouse enucleated oocyte
so that the resulting clone expresses the condition in a
patient-specific way. Hence, clinical testing would be
done on the animal model to find an optimal treatment,
such as the drug combination to treat epigenetically-
triggered cancer, highly variable among instances.  
CANCER DIAGNOSIS
SCNT has applications in cancer research to
identify whether a particular type of cancer arises from
a genetic or an epigenetic defect (15), such as the
demethylation of a tumor suppressor gene. The
epigenetic modifications of chromatin structure in
cancerous cells involve altered histone methylation,
phosphorylation and deacetylation, as well as DNA
methylation, which are reversible unlike genetic
mutations. Supportive evidence for oncogenesis
resulting from epigenetic features includes studies
where normal mice blastula were obtained through
SCNT from a skin malignancy (16) and a medullar
a scaffold (39) holds great hope in the treatment of
infarctus, atherosclerosis and severe burns, respectively.
Consequently, the feasibility of de novo organogenesis
based on SCNT depends on the elucidation of the
tissue-specific molecular pathways mediating
differentiation as well as the improvement of current
SCNT and tissue engineering methods in order to
recreate in vitro the complex three-dimensional
organization and different intercellular interactions in
organogenesis.
D'Amour et al designed in 2006 a five-step protocol
enabling human embryonic stem cells to differentiate
into endocrine cells producing most pancreatic
hormones (10), including glucagon and insulin, with
implications for use in cell replacement therapy for the
treatment of diabetes mellitus. The combination of
growth factors and differentiation markers added at
each stage of the method were designed to duplicate
pancreatic organogenesis in vivo, a breakthrough which
could concretize the hope of generating organs using
therapeutic cloning. According to this protocol, patient-
specific ntESC lines would be differentiated into
successive cell-type intermediates representative of
pancreatic organogenesis, from endoderm to the
terminally differentiated ß-cell that would then be
transplanted into the patient's pancreas to treat diabetes-
related hyperglycemia. 
The recent success of therapeutic cloning in a mouse
model of Parkinson’s disease foreshadows clinical
applicability in humans to treat neurodegenerative
diseases and conditions involving demyelination.
Parkinson’s disease is characterized by the deterioration
of dopaminergic neurons resulting in constant tremor
and muscular stiffness impairing motility. Barberi et al
derived, by SCNT with somatic nuclei from mouse
cumulus and tail-tip cells, two ntESC lines which were
induced to differentiate into motor, GABAminergic,
serotonergic and dopaminergic neurons (11) forming
synapses and displaying normal electrophysiological
properties in vitro. The dopaminergic neurons were
directly injected into the cortical striatum of mice with
Parkinson-like lesions induced by 6-hydroxydopamine.
Long-term behavioral rescue was observed, and 80% of
the ntESC derived neurons were alive 8 week post-
transplantation, contrary to only 40% for stem cell-
derived neurons. Hence, the therapeutic cloning
approach was shown to be more permanent as a cell
replacement therapy and could eventually be extended
to the treatment of cortical atrophy resulting from stroke
or Alzheimer's disease.
REJUVENATING POTENTIAL
It has been observed that the SCNT of the nucleus of
a cell close to reaching senescence resets the lifespan of
the cell, as seen by the ability of the resulting embryo to
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(DMD) is an inheritable X-linked condition
characterized by reduced intramuscular dystophin
levels, causing cellular necrosis and weakening (23).
Being a single-gene disorder, DMD can be treated by
therapeutic cloning in combination with gene therapy to
restore normal dystrophin production. In the case where
ntESC are transplanted without prior differentiation in
vitro, the insertion of a transgene encoding MyoD (35),
a transcription factor responsible for commitment to the
myogenic lineage, may promote muscle regeneration.  
The combination of gene therapy and therapeutic
cloning has exciting potential for the genetic rescue of
missing alleles in heritable genetic disorders such as
severe combined immunodeficiency (SCID), in which
genetic mutations of specific genes such as RAG-1 and
2, essential for the DNA recombination allowing
immunoglobulin and lymphocyte polymorphism,
render the immune system completely inefficient.
Hochedlinger et al took a somatic nucleus from the tail-
tip of an SCID mouse-model, created through the
double-knockout of the Rag-2 gene (recombination-
activating gene 2), and rescued the genetic defect
through the insertion of two copies of the Rag-2 gene by
homologous recombination (24). SCNT was performed
to clone viable Rag-2 (+/+) mice with a normal immune
system, from which embryonic stem cells were
differentiated in vitro into hematopoietic stem cells
normally found in the bone marrow. Three weeks
following transplantation into the Rag-2(-/-) knockout
mouse model, partial rescue of immune function was
observed, as well as the presence of lymphocyte
precursors and functional antibodies. However, mature
T lymphocytes were not observed, suspected to be due
to selective differentiation of the transplanted stem cells
into myeloid cells (bone marrow precursors) instead
(25). Although more work needs to be done to elucidate
the pathways leading to preferential differentiation in
vivo, the combination of gene therapy for the rescue of
a loss of function and therapeutic cloning to bypass
graft rejection holds the potential to eventually cure
other immune disorders. Oncogenic activation
following transduction constitutes a major drawback to
this approach. In 2002, the insertion of the transgene to
treat X-linked SCID in the LMO2 oncogene caused the
onset of leukemia in two out of seven patients recently
treated (26). Repeated graft rejection, even when
derived through SCNT, remains an unsolved problem in
the case of autoimmune disorders such as pernicious
anemia and multiple sclerosis.  
ROADBLOCKS OF THERAPEUTIC CLONING
Legal and funding issues
Legislative constraints and the subsequent lack of
funding constitute a major impediment to the
tumor (17). These studies could lead to clinical
applications for cancer diagnosis in humans since
nuclear reprogramming signals from the host ooplasm
variably reset the epigenetic profile of the nuclear donor
DNA. The derivation through SCNT of a healthy
patient-specific stem line would show that cancer onset
was triggered by epigenetic alterations. Anti-
methylation drug, such as 5-aza-2'-deoxycytidine
inhibiting DNA methyltransferases (18) that inactivate
apoptotic genes in cancerous cells and histone
deactylase inhibitors against oncogene overexpression
are currently under clinical trial (15) as a potential anti-
cancer therapy. 
However, epigenetic resetting (15) following
SCNT is likely to disrupt normal phenotype of the
embryo-derived cell lines and the adult clone, the latter
displaying an abnormally low body weight and
expression level of MUP encoding genes (Major
Urinary Proteins) as shown by Reik et al in the mouse.
The epigenetic pattern of imprinted genes that was
established during gametogenesis is lost through SCNT
(20) and the inactivation of early genes directing
embryogenesis can explain low embryo viability and
poor efficiency in the derivation of autologous ntESC
lines. Blelloch et al found out, from studies on neurons,
that stem cells used as the nuclear donor have a higher
success rate (21) than fully differentiated cells in the
derivation of autologous embryonic cells. The
introduction of a genetic mutation to reduce the
function of DNA methyltransferase-1, as investigated
by the same team, improved the production of ntESC
due to resulting "global hypomethylation" (22) of
genomic nuclear DNA.  
THERAPEUTIC CLONING IN THE CONTEXT
OF GENE THERAPY:  CURRENT HOPES AND
DRAWBACKS 
SCNT from genetically modified nuclei obtained
from a patient's skin biopsy, for example, is an efficient
strategy to restore normal expression of a missing factor
or to facilitate in vivo survival of the graft generated.
For instance, patient-specific cardiomyocytes produced
through SCNT will not integrate into the scarred heart
tissue resulting from myocardial infarction. A proposed
strategy (39) would be the genomic integration of an
exogenous gene, prior to transplantation, encoding an
anti-scarring factor (22) such as TGF-ß (transforming
growth factor-ß). In the case of haemophilia,
characterized by a deficit in functional clotting factor
IX and XIII (39), the addition of the genetically
engineered missing DNA sequence, or the replacement
of the dysfunctional gene through homologous
recombination in a patient's biopsy prior to SCNT could
produce patient-specific cell lines with a correction for
the defect. 
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informed consent. Eggan and Melton intend to generate
human ntESC lines from patients with diabetes, sickle
cell anemia and amyotrophic lateral sclerosis  (ALS), a
progressive neurodegenerative condition targeting
motor neurons (31). 
Possible solutions to the oocyte shortage for
therapeutic cloning 
Interestingly, SCNT could provide a solution to low
human oocyte availability and a promising therapeutic
approach to circumvent infertility. As reported by Nagy
and Chang, artificial gametes (32) can be created by
haploidization, through SCNT into an enucleated
oocyte ready to undergo meiosis upon induction.
Tesarik et al incorporated the nucleus of a human
cumulus cell into an enucleated allogenic oocyte. They
got a 50% success rate in haploidization, and two out of
the six artificial oocytes were successfully fertilized in
vitro and thawed for possible implantation later on (33).
However, abnormal chromosomal segregation and
mitotic spindle assembly, as observed in mice, need to
be resolved before haploidization through SCNT can be
safely wide-spread in fertility clinics.
Once the molecular pathways of oocyte maturation
are resolved, immature follicles could be collected post-
mortem (39) and induced to mature in vitro for research
purpose. However, this option needs to be rigorously
regulated, and is likely to stir an ethical controversy.
An alternative to low human oocyte availability
would be to use an oocyte of a different species.
Successful trials were done to generate blastocysts in
vitro through the SCNT of skin fibroblast nucleus from
different mammals (ungulates, rodents, pigs, monkey)
(34)  and human into an enucleated bovine oocyte.
However, only 1% of the human-bovine hybrids
developed beyond the 16-cell stage, allowing the
derivation of a human ntESC line (39). The insertion of
human nuclear genome into an animal oocyte,
especially through electrofusion where both human and
animal mitochondrial DNA coexist in the same
ooplasm, raise objections among the detractors of
therapeutic cloning, although the percentage of total
residual animal DNA (nuclear and mitochondrial) is too
low to consider the hybrid as a chimera.  
Mitochondrial heteroplasmy
Immune rejection of the ntESC in cell replacement
therapy is due to mitochondrial heteroplasmy as a
consequence of SCNT since the nuclear donor and
ooplasmic host cells are not autologous in most cases.
Mitochondrial heteroplasmy is also a major cause of
SCNT embryo inviability beyond the eight-cell stage
because the mitochondrial-nucleus interactions
necessary for the production of most mitochondrial
advancement of therapeutic cloning. For instance,
although therapeutic cloning is not completely banned
in the United States, federal funding is not permitted to
be used in experiments involving the 20 cell lines in the
NIH (National Institute of Health) registry (44) derived
before August 9, 2001. Out of these cell lines approved
by Bush, 12 died and the remaining is not useful for
research purposes. Researchers have to therefore rely on
the scarcity of private funding, although 4 American
states, including California with a yearly investment of
295 millions, have a budget allowed specifically for
stem cell research (44). Clinton expressed concern on
chimera production through “experiments involving the
mingling of human and non-human species” (58) but
paradoxically all the cell lines in the NIH registry that
got Bush's approval were grown on animal-feeder cell
layers and therefore contain traces of animal
contaminants. 
Oocyte availability: regulations and ethical concerns 
A major roadblock in the feasibility of human
therapeutic cloning is the low availability of oocytes for
research purposes. Currently, due to low SCNT
efficiency, it is estimated that 280 human oocytes (35)
would be needed in order to derive one observe patient-
specific ntESC line. The Human Fertility and Embryo
Authority, in England, allows women in fertility clinics
to offer two oocytes for scientific research, provided
that at least twelve oocytes are collected (25), although
the extra oocytes taken are more likely to be donated for
in vitro insemination. Oocyte donations are, by law,
forbidden to be remunerated other than to reimburse the
cost of the procedure (from 1000 to 2000$) for ethical
reasons. Substantial financial gain would incite poorer
women to surrender of part of a finite supply of
gametes, in addition to the risks incurred through
surgerical removal of the oocytes and hormonal
treatments. Ovarian hyperstimulation syndrome
(OHSS) results, in most cases, from the administration
of drugs such as gonadotropin-releasing hormone
agonists (27), to induce the simultaneous maturation of
multiple follicles into oocytes. OHSS can lead to
cardio-respiratory difficulties, renal problems and
internal hemorrhage, due to the accumulation of fluid in
the abdominal cavity caused by abnormal vascular
permeability in the vicinity of the ovaries (28), and
occurs in 2 to 5% of the patients (29).   
Fertility clinics are the major source of human
oocytes for research. The aged oocytes that did not
fertilize during in vitro trials are not optimal for SCNT,
as investigated by Hall et al, who observed
overexpression of genes encoding for meiotic spindles
proteins and a lower cleavage efficiency (30) of aged
oocytes versus fresh ones. After two years of debate,
Harvard is the only group currently allowed to use
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with animal-derived serum, the stem cells incorporate
enough Neu5Gc to potentially elicit an immune
response  (45) in vivo, hence killing the transplanted
cells. Although the murine leukemia virus is not
pathogenic (44) when transmitted from mouse feeder
cells to human ntESC, non-cellular matrices are being
designed to counteract the problem of animal
contaminants. Ludwig et al developed a combination of
human growth factors (TGFß, LiCl, bFGF, GABA,
pipecolic acid which enhances receptor sensitivity to
GABA) on a basal lamina reconstituted in vitro with
human extracellular matrix components (collagen IV,
laminin, vitronectin and fibronectin) (46)  as a substitute
for an animal feeder-cell layer. Neu5Gc was not
reported in the cell lines cultured on this human matrix.
In sum, the issue of pathogenic transmission is in the
process of being solved, bringing one step further the
potential for clinical application of therapeutic cloning
in cell replacement therapy. 
Tumorgenesis and spontaneous differentiation
NtESC are subjected to the same tumorigenicity
potential as wild-type stem cells. The formation of
teratomas, after in vivo transplantation, is due to co-
purification of pluripotent stem cells along with the
wanted differentiated cells. Fujikawa et al noted tumor
formation in the ß-pancreatic cells transplanted in
diabetic mice (47). The teratomas resulted from a low
concentration of 0.2% Oct4 and SSEA-1 positive cells,
both markers of pluripotency (48) downregulated upon
differentiation, indicating the presence of left-over
undifferentiated stem cells. Although the hyperglycemia
associated with type I diabetes was reversed,
tumorgenesis occurred 20 days post-transplantation,
rendering stem cells, whether wild-type or issued from
therapeutic cloning, a non-viable option for clinical
applications in this instance, unless better isolation
methods for the exclusive purification of differentiated
stem cells are designed. 
ETHICAL CONSIDERATIONS
Destruction of IVF
Therapeutic cloning and stem cell research stir an
ethical controversy due to the source of embryonic stem
cells, taken from aborted fetuses, unutilized zygotes
(49) and embryos morphologically incapable of in utero
implantation, the latter representing 60% of all embryos
(50)  created through IVF. Some consider the use of
discarded embryos diminutive since they imply
"recycling" life products, as implied by Bush's
statement that "there is no spare embryo (29)."  
The apparition of the primitive streak directing
polarized development confers to the two-week embryo
a higher moral status  (51) as a potential human
proteins are disrupted due to inter-species
incompatibility (35). Also, antigens such as Mta are
encoded by the mitochondrial genome and trigger an
auto-immune response targeting the hybrid (36) after
transplantation. Cyclosporine A, an immunosupressor
drug already used in organ transplantation (37), and the
addition of either hemoglobin or ß-mercaptoethanol
might inhibit mitochondrial-induced apoptosis in the
ntESC. Inter-species incompatibility can be
circumvented to a certain degree if the donor and host
species are closely related. For instance, embryonic
cells derived from the injection of a human nucleus in a
chimpanzee ooplasm were viable, contrarily to when
SCNT was done with the ooplasm of a nonhuman
primate such as the orang-utan (39).
The transfer of mitochondria isolated from patient-
specific biopsies (39) might circumvent the immune
rejection problem due to mitochondrial heteroplasmy,
and a female patient could in theory donate both the
somatic nucleus and oocyte necessary for cell
replacement therapy in her own body. The latter option
offers great promises since recent studies in bovine
showed that autologous SCNT embryonic production
was more efficient than when the nuclear donor and
ooplasmic host are from allogenic origins, and
epigenetic reprogramming occurs to a significantly less
extend in autologous SCNT embryos (40).  
Transfer of animal contaminants
The interspecies transmission of pathogens is a non-
negligible issue when injecting a human nucleus into
the oocyte of another species, such as bovine or pig
(41). For instance, the porcine endogenous retrovirus
(PERV), although inoffensive in pigs, disrupts the
transcription initiation of genes in humans, as
demonstrated in vitro by Moalic et al, by integrating
within the CpG islands of promoters (42). Gene therapy
approaches are being designed to reduce the infectivity
of PERV due to the mannose-rich N-glycan integrated
in the viral capsule (43). Thus, through the insertion of
genes such as ManIb and ManII, encoding
mannosidases involved in N-glycan catabolism, the
infectivity of PERV was significantly reduced but not
annihilated in human cells. 
Animal serum and non-proliferative mouse fibroblast
used as feeder-cell layer to direct the development of
the human ntESC (44) is problematic since animal
contaminants can be transferred to the ntESC which in
turn might trigger an immune response post-
transplantation, thereby revoking the goal of therapeutic
cloning. 
N-glycolylneuraminic acid (Neu5Gc) is a mammalian
sialic acid (a sugar with acidic side-chains present in the
membrane of all cells) not found in humans, although
most of us have anti-Neu5Gc antibodies. When human
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idea that the potential to become a person confers a
special moral status is plausible, if at all, only if the
potential is identity-preserving (56). " He further argues
that, contrary to the late-term embryo, the early embryo
as an "insentient cluster of cells" has nonidentity
potential since the latter is not identical in morphology
to the mature organism, which possesses a neuronal
network characteristic of higher mental life, is able to
develop complex cognitive capacities including self-
consciousness and sentience, of which the early-term
embryo is deprived. The destruction of an embryo of
lower moral significance in the context of justified
research to improve the quality of life of existing people
of higher moral status ought to be viewed as morally
permissible. Furthermore, under the philosophical point
of view, "cell replacement therapy does not involve the
destruction of an embryo but only its transformation
into an embryonic cell line (57)." 
The engineering of mouse blastocysts lacking the
Cdx2 gene , otherwise needed for the generation of the
midgut endoderm and trophoblast differenciation,
results in non-viable embryos that spontaneously stop
dividing, providing a criticized alternative to the
destruction of embryos by deliberate human action. 
CONCLUSION
Although several scientific roadblocks remain
unsolved, the medical benefits that could be gained
from treatments based on therapeutic cloning outweigh
the ethical dilemma and calls for further improvements
to be clinically applicable. In sum, therapeutic cloning
features great potential as a histocompatible method for
cell replacement therapy to restore motility following
paralysis, counteract senescence, and repair damages
done by stroke, myocardial infarction, liver cirrhosis,
severe burns and osteoporosis to name a few. Used as an
alternative to viral vectors, patient-specific cell lines
derived through SCNT can be used in conjunction with
gene therapy to treat conditions caused by genetic
defects among which diabetes, hemophilia, sickle cell
anemia, SCID, neurodegenerative disorders such as
Parkinson, DMD and many more. Transgene insertion
could be used before in vivo transplantation of the
ntESC in order to enhance graft survival, differentiation
and integration. Other applications of therapeutic
cloning include the diagnosis of epigenetically triggered
cancer and the tailoring of a treatment using SCNT, the
creation of animal models of human diseases, and could
eventually lead to tissue engineering of organs de novo.
Main scientific difficulties include tumorigenicity, in
vitro spontaneous differentiation, interspecies transfer
of pathogens, low oocyte availability, epigenetic
reprogramming of the genome, mitochondrial
heteroplasmy and the possibility of graft rejection.
organism, compared to the earlier embryo at the stage of
a randomly-organized group of cells. Consequently,
laws prohibiting the culture of embryos for more than
two-weeks, which marks the onset of gastrulation and
the formation of the primitive streak, are in vigor in
several countries such as the United States, based on a
decision of the British Warnock Commission (29) in
1984. 
The ethical debate on the moral impermissibility of
deliberate destruction of an embryo can be
circumvented by a new technique deviced by Chung et
al. They successfully derived human ESC from a single
cell without destroying the blastocyst in the process
(52), using the same manipulations normally devoted to
genetic screening in preimplantation embryos. This
method seems to be promising for solving the ethical
concern of killing a human embryo, rendering feasible
the pre-natal generation of individual-specific cell lines
for use in regenerative medicine later on in life.
However, Chung's method does not modify the fate of
the ex vivo embryo, since the latter has a slim chance of
implantation. 
Moral status of the IVF embryo and the argument of
potential
The main ethical roadblock against therapeutic
cloning is the destruction of the generated embryos in
order to collect cells that would further be differentiated
in vitro. Embryo destruction is viewed as morally
objectionable by the Prolife partisans because they
grant the early embryo potential for personhood
following development to term. Knowing that only 1 to
2 % of cloned mice produce viable organisms (53), the
probability of producing a viable cloned human embryo
is even slimmer. However, the detractors of research
using embryos would argue that the potential for
personhood ought not to be granted on the basis of
probability because a minority - one out of three (54)  -
of zygotes conceived by natural means might implant in
utero and be carried to term. Hence, the argument from
potential relies on possibility rather than probability and
is based on the belief that morally significant human life
beings at conception. According to Dawson and Singer,
"since something is logically impossible only if its
assertion involves a contradiction, it is not logically
impossible for a human blastocyst in a laboratory to
develop into a person (55)." 
A counterargument put forth by the advocates of
embryo research is that, left untouched, it is impossible
that the in vitro embryo develops into the mature
organism, and in utero implantation cannot occur if the
transferred embryo reached the eight-celled stage and
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generate a SCNT embryo that would have otherwise not
existed, therefore we are not morally obligated to
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scarring and a potential target for anti-scarring gene therapy. 
Curr Gene Ther 2004 Mar;4(1):123-36. Review.
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potential for muscle regeneration. Birth Defects Res C Embryo
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transplantation and combined cell and gene therapy. Cell. 2002
Apr 5;109(1):17-27. 
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fight human disease: a conundrum or reality? Stem Cells. 2006
Jul; 24(7):1628-37. Review. 
26.   Chinen J, Puck JM. Successes and risks of gene therapy in 
primary immunodeficiencies. J Allergy Clin Immunol. 2004 
Apr;113(4):595-603. Review. 
27.   Acevedo B, Gomez-Palomares JL, Ricciarelli E, Hernández 
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Fertility and Sterility 2006 Dec; 86(6):1682-7. 
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29.   Okie S. Stem-cell research--signposts and roadblocks. N Engl J
Med. 2005 Jul 7;353(1):1-5. 
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Reproduction 2006 Sept 6. 
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Ethical controversy on the source and destruction of
embryos as well as the contradictory legislations and
scarcity of funding contribute to impede advancements
in therapeutic cloning. Future considerations would be
to unify federal and state laws, and establish a clear
distinction between therapeutic and reproductive
cloning in the redaction of laws pertaining to the SCNT
generation of embryos. In this regard, a close
understanding of the science and ethical issues
pertaining to therapeutic cloning is necessary to ensure
improvement in clinical applicability without falling
into unregulated abuses. 
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